<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917175</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 1220/12277 PRECO-CI</org_study_id>
    <nct_id>NCT01917175</nct_id>
  </id_info>
  <brief_title>Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire</brief_title>
  <acronym>PRECO-CI</acronym>
  <official_title>Research Platform &quot; Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire &quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Set-up of a biobank for patients with an estimated date of infection seroconverters: store
      plasma and cells samples at initial contact and during follow-up for future analysis and
      analysis in international collaborative cohort seroconverters.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 1997</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Natural history of HIV infection in Sub-Saharan Africa</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Plasmatic HIV viral load and CD4 measured every six months and incidence of morbidity events associated with AIDS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the probability of disease progression after HIV seroconversion</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Disease progression will be estimated with CD4 cell loss and time from seroconversion to clinical AIDS, death and antiretroviral therapy initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of markers of HIV infection and immunity</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>CD4 count, immune activation, plasma HIV-RNA intracellular, HIV-DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral genetic diversity description</measure>
    <time_frame>Inclusion (J0)</time_frame>
    <description>biomolecular analysis of HIV-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary resistance to antiretroviral treatment</measure>
    <time_frame>Inclusion (J0)</time_frame>
    <description>Frequency of primary resistance to antiretroviral treatment (genotyping)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic and lipodystrophic disorders</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Metabolic analysis (Total Cholesterol, HDL and LDL, Triglycerides) and lipodystrophia measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pregnancies</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Occurence of pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T lymphocytes activation and evolution in seroconverters</measure>
    <time_frame>Inclusion</time_frame>
    <description>Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T lymphocytes activation and evolution in seroconverters</measure>
    <time_frame>12 months after ART initiation</time_frame>
    <description>Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">564</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>HIV+ patients with an estimated date of seroconversion</arm_group_label>
    <description>It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and whole blood for PBMC preparation
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All HIV infected individuals that will have had a contact with the Blood Bank Medical
        Center since 1992.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients included in the last Primo-CI ANRS 1220 protocol

          -  All HIV infected individuals diagnosed during a blood donation with an estimated date
             of HIV seroconversion that will respect the following criteria: (i) age ≥18 (ii) HIV-1
             or HIV-1+2 infected, (iii) HIV-seronegative at the preceding donation; (iv) who
             returned to the clinic to be informed of their HIV test result (v) with an HIV
             serology confirmed with two specific tests in two different laboratories (vi) who have
             never received ART for curative purpose

          -  informed on study objectives and have a signed informed consent.

        Exclusion Criteria:

          -  Patient living outside of Abidjan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Kla Minga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CMSDS, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Coffie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Programme PACCI, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlotte Lewden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albert Minga, MD, PhD</last_name>
    <phone>+225 21 35 52 78</phone>
    <email>minga.albert@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Coffie, MD, PhD</last_name>
    <phone>+225 21 75 59 60</phone>
    <email>ahuatchi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Médical du Suivi des Donneurs de Sang (Blood Bank Medical Centre)</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Kla Minga, MD, PhD</last_name>
      <phone>+225 21 35 52 78</phone>
      <email>minga.albert@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre National de Transfusion Sanguine (National Blood Transfusion Centre)</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seidou Konaté, MD</last_name>
      <phone>+22521355723</phone>
      <email>plasmaci@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <link>
    <url>http://anrs.fr/</url>
    <description>Sponsor site</description>
  </link>
  <link>
    <url>http://mereva.net</url>
    <description>Methodology centre site</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>August 5, 2013</last_update_submitted>
  <last_update_submitted_qc>August 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Cohort</keyword>
  <keyword>Early HIV infection</keyword>
  <keyword>Côte d'Ivoire</keyword>
  <keyword>Disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

